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Short Summary 
 
In a cohort of HIV high-risk women, assigning random-point values as the seroconversion timing 
attenuated variation in incidence observed with the mid-point assignment during observation 
periods with longer seroconversion intervals. 
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Abstract  
 
Background: High attrition and irregular testing for HIV in cohort studies for high-risk 
populations can bias incidence estimates. We compare incidence trends for high-risk women 
attending a dedicated HIV prevention and treatment clinic, using common methods for 
assigning when seroconversion occurs and whether seroconversion occurs among those with 
attrition. 
 
Methods: Between April 2008-May 2009 women were enrolled into cohort-1 and from January 
2013 into cohort-2, then scheduled for follow-up once every three months. Incidence trends 
based on assuming a mid-point in the seroconversion interval were compared to those of 
assigning a random-point. We also compared estimates based on the random-point with and 
without multiple imputation (MI) of sero-status for participants with attrition.  
 
Results: By May 2017, 3084 HIV-negative women had been enrolled with 18,364 clinic visits. 
Before attrition, 27.6% (6,990/25,354) were missed visits. By August 2017, 65.8% (426/647) of 
those enrolled in cohort-1 and 49.0% (1194/2437) in cohort-2 were defined with attrition. 
Among women with ≥1 follow-up visit, 93/605 in cohort-1 and 77/1601 in cohort-2 
seroconverted. Periods with longer seroconversion intervals appeared to have noticeable 
differences in incidences when comparing the mid-point and random-point values. MI for 
attrition is likely to have overestimated incidence following escalated attrition of participants. 
Based on random-point without MI for attrition, incidence at end of observation was 3.8/100 
person-years in cohort-1 and 1.8/100 in cohort-2. 
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Conclusion: The random-point approach attenuated variation in incidence observed using mid-
point. The high incidence after years of ongoing prevention efforts in this vulnerable population 
should be investigated to further reduce incidence. 
 
Key words: HIV, incidence, high-risk, imputation, Uganda 
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Introduction  
 
Monitoring HIV incidence rates over time facilitates informed public health decisions on HIV 
prevention and treatment. Longitudinal studies are commonly used to estimate incidence rates 
where test dates are scheduled at fixed time intervals of, say, every month or year
1
. The timing of 
a new infection can be assumed to be within the seroconversion interval of the last-negative and 
first-positive test dates, as either the mid-point or a random-point value. Recently, these two 
popular approaches for identifying the timing of seroconversion in estimating incidence rates 
have been discussed but little is still known about how these approaches influence interpretation 
of HIV incidence trends under different circumstances in cohorts for women at high risk of 
HIV
2
.  
 
Globally, HIV risk was 13 times higher among female sex workers (FSWs) than among other 
adult women
3
. HIV incidence in FSW studies in eastern and southern Africa is as high as 9.8/100 
person-years
4
. In Uganda, where adult female HIV prevalence is 7.5%, estimated prevalence 
among FSWs varies between 32%-52%
5,6
. 
 
Using data on HIV-1-specific immunoglobulin G (IgG) levels that indicates if a patient was 
infected recently, assuming the mid-point value while estimating incidence was appropriate for 
cohort studies with regular testing intervals
7
. However, a recent simulation study estimating 
incidence trends demonstrated that, in the presence of missed scheduled testing, the mid-point 
approach leads to an artefactual clustering of seroconversion times in the middle of the 
observation period
2
. As a result, incidence rates are under-estimated at the beginning and at the 
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end of the observation period, and over-estimated in the middle. For example, incidence rates at 
the end of the observation period were in error of 27% for a simulated cohort with a 40-59.9% 
testing rate. An alternative approach that randomly assigns the timing of seroconversion within 
the seroconversion interval produced less biased incidence trend estimates
2
.  
 
Several factors can lead to varying visit attendance rates during observation. In follow-up studies 
of long durations,  later observation periods usually have poorer attendance rates than earlier 
ones, partly due to participation fatigue
8
. Changes in certain cohort activities such as removing 
transport refund can also influence levels of attendance during those periods. In particular, 
cohorts for high-risk populations are vulnerable to missing visits and prematurely discontinuing 
participation (attrition) because of the high mobility of participants, and transport costs among 
other reasons
9,10
.  The longer seroconversion intervals due to missed visits create larger 
uncertainty over when the event occurs, and attrition leads to uncertainty of whether the event 
occurs for participants defined with attrition. These uncertainties can compromise the 
interpretations of HIV incidence trends
8
. Participants with attrition are usually censored at their 
last observation, while assuming their risk of infection at censoring is the same as that in those 
under observation at that time-point. If this assumption is violated, for instance if women who 
discontinue are at a higher risk of HIV than those who remain in the study, then there is potential 
for bias in incidence estimates. Given the cohort experience of participants without attrition who 
have similar characteristics as those with attrition, using multiple imputation (MI) to predict 
unobserved HIV sero-status and timing of seroconversion for women with attrition could 
improve the accuracy of incidence estimates
11
.  
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In this paper, we aim to compare HIV incidence trends based on three approaches: (1) estimating 
the date of seroconversion within the seroconversion interval using the mid-point; (2) estimating 
the date of seroconversion within the seroconversion interval using the random-point method; 
and (3) predicting the time-to-event data using MI for women with attrition. These comparisons 
are performed in the epidemiological context of a dedicated clinic which has been providing 
services to women at high risk of HIV in Kampala, Uganda since 2008. 
 
Methods 
 
Cohort description 
 
The Good Health for Women Project (GHWP) is a stand-alone clinic offering free services to 
women at high risk of HIV-infection in Kampala, Uganda
12
. Briefly, peer educators recruited 
other women involved in commercial sex or employed in an entertainment facility within 
mapped sex work hotspots (e.g., clusters of bars, night clubs, lodges and guest houses providing 
rooms for sex work, street spots frequented by sex workers). Outreach workers visited these 
women at their workplace to assess eligibility. Women were eligible if aged ≥18 years and 
reported engaging in commercial sex (self-identified FSWs or received money, goods, or other 
favours in exchange for sex) or employed in an entertainment facility. Women <18 years were 
eligible if pregnant, had a child, or provided for their own livelihood. Those eligible were invited 
to attend the clinic for screening and enrolment. 
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Women were initially enrolled into cohort-1 between April 2008 and May 2009 and continually 
scheduled for follow-up once every three months. Previous publications on this cohort have 
examined prevalence of HIV and other STIs at baseline
12
, HIV incidence and risk factors using 
data up to March 2011
13
, and the epidemiology of alcohol use until September 2013
14
. Cohort-2 
was started in January 2013 with continuous enrolment of participants and identical follow-up 
procedures as cohort-1. This paper considered follow-up visits up to 29
th
 August 2017 for both 
cohorts. 
 
Study intervention 
 
The programme integrates sex worker friendly HIV and sexual and reproductive health services, 
including offering free general health care for participants and their children aged <5 years old. 
Figure 1 shows a summarised conceptual framework guiding the GHWP intervention derived 
from the standard framework for preventing HIV acquisition in FSWs developed by WHO. The 
intervention can be categorised into three broad components (behavioural, biomedical, structural) 
aiming at three broad categories of immediate outcomes: reducing unprotected sex; decreasing 
HIV transmission efficiency; and empowering FSWs
15,16
. The horizontal arrows depict the link 
from the intervention to the intermediate effects, which in turn determine the impact on HIV 
acquisition and transmission. The vertical arrows show the factors that can influence the 
immediate intervention effects, and the transition to HIV prevention indicators. To ensure high 
cohort retention, group meetings were held every 14 days with women who had scheduled visits 
within the following month. Participants with two or more missed visits were contacted by phone 
or visited and encouraged to attend.  
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Data 
 
At every visit, HIV testing was performed using determine HIV-1/2 (Abbott Diagnostics, UK) 
for screening and a reactive result was confirmed by Stat-Pak dipstick HIV-1/2 (Chembio 
Diagnostics, US). The Uni-Gold HIV-1/2 (Trinity Biotech, Ireland) was used as a tie breaker if 
Determine and Stat-Pak were discordant. At every visit, trained nurse-counsellors administered 
structured questionnaires to collect data on socio-demographic characteristics, sexual behaviour, 
reproductive health, alcohol use, and illicit drug use. 
 
Statistical analysis 
 
Analyses were restricted to HIV-negative women enrolled before May 2017 to allow for follow-
up visits for all participants. In estimating incidence, the endpoint for calculating person-years at 
risk was the earliest of i) estimated HIV seroconversion date for seroconverters or ii) last HIV-
negative test date for non-seroconverters. 
 
HIV seroconversion date was estimated using (a) mid-point between last-negative and first-
positive HIV test dates; (b) random-point method. The random-point method assumed 
seroconversion to be a random date from a uniform distribution bounded by the last-negative and 
first-positive test dates. To account for the variability of using a random date, multiple 
imputations were made, and incidence rates over time were estimated each time and averaged at 
each time-point for all iterations.  
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To assess the potential consequence of attrition on incidence trends, we imputed the unobserved 
HIV sero-status then obtained timing for seroconversion for participants with attrition. Several 
methods for imputing unobserved time-to-event endpoints have been published
17,18
. Since our 
interest is incidence trends evaluated at time intervals of follow-up, we applied an MI approach 
that models the probability of seroconversion within each time interval given that the participant 
was HIV-negative up to the start of that interval. In this approach the follow-up period is divided 
into discrete intervals of time and logistic regression used to impute sero-status sequentially in 
each interval. Then, the imputed sero-statuses are mapped back to the time-scale by allocating a 
random time within the seroconversion interval, and censoring at each participant’s expected 
complete follow-up time for imputed non-seroconverters. Estimates were based on 200 
imputations. The log of incidence rates at each time-interval were estimated separately in each 
imputed dataset, then averaged using Rubin’s rules19. Statistical tests assessing whether the age-
adjusted incidence trends changed over time in each imputed dataset were combined after 
normalisation using Wilson-Hilferty transformation
20
. 
 
The imputation model included factors associated with both attrition and HIV incidence in this 
analysis. To improve imputation accuracy of sero-status, we included as a-priori the age, and 
time-varying characteristics of: frequency of alcohol consumption, reporting paid sex, condom 
use frequency with paid sex and number of partners in the last month in the imputation models. 
To identify factors associated with attrition, the outcome was time-to-attrition, and follow-up 
was right-censored at last observation. A participant had attrition if their last study attendance 
was 12 months or more prior to the administrative censoring date, consistent with what has been 
used in other studies. To investigate factors associated with attrition and then incidence, hazard 
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ratios (HRs), and associated 95% confidence intervals (CI) and p-values were estimated using 
Cox regression models. Age-adjusted models were fitted separately for each factor and 
independently associated sociodemographic factors (p-value≤0.15) were determined. These were 
then adjusted for behavioural and reproductive health factors that remained statistically 
significant at 15% level. Time-changing variables were fitted using the most recent reports at 
each visit.  
 
Analyses were performed separately for each cohort because of the potential variation in 
exposures due to the five-year gap between the starts of the two cohorts. For each cohort, 
estimates of incidence trends from three models were compared: 1) Without MI using mid-point; 
(2) Without MI using random-point; (3) MI using random-point. Changes in incidence trends 
were assessed using Poisson regressions models by testing the inclusion of a linear and a 
quadratic trend with time in models adjusted for current age. Stata 14 (StataCorp, Tx) was used 
for all analyses. 
 
Results 
 
HIV prevalence at enrolment was 37.0% (380/1027) in cohort-1 and 35.4% (1335/3772) in 
cohort-2. Table 1 shows enrolment characteristics for the 3084 HIV-negative women. Overall, 
the mean age was 26.2 years (SD: 6.3) with over 80% having ≥1 child. Most (58.0%) reported 
their only source of income as sex work, and 37.2% reported having another job in addition to 
sex work.  
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Attrition and missed visits 
 
The percentage of women with ≥1 follow-up visit was 93.5% (605/647) in cohort-1 and 65.7% 
(1601/2437) in cohort-2. A total of 32,762 visits (Cohort-1:17,970; Cohort-2:14,792) were 
expected while 18,364 (Cohort-1: 9,504; Cohort-2: 8,860) were made. Before attrition, 6,990 
visits (Cohort-1:3,324; Cohort-2:3,666) were missed and 7,408 (Cohort-1:5142; Cohort-2:2266) 
after attrition. Table 1 SDC link http://links.lww.com/OLQ/A343 shows study participation and 
the supplementary Table 2 SDC link http://links.lww.com/OLQ/A344 shows the factors 
associated with attrition. Attrition was independently associated with follow-up characteristics of 
having no child, being pregnant, recruiting clients on phone, and reporting no illicit drug use in 
the last 3 months in cohort-1 and younger age, not using oral contraceptives, and less frequent 
paid sex in the last year in cohort-2. The percentage of participants attending each visit with ≥1 
missed visits since the previous attendance in cohort-1 was stable at 10% until year four, when 
this proportion increased to an average of 30% for all the visits after year four (Figure 2). In 
cohort-2, this proportion was stable at 30% for all the visits following enrolment. 
 
HIV incidence 
 
Among 2206 HIV-negative participants with ≥1 follow-up visit, 170 were observed to 
seroconvert within 5540 person-years. Without MI, the mid-point and random-point incidence 
trends were similar in the first four years of enrolment and at years 7 and 8 of cohort-1 (Figure 
3). At the introduction of cohort-2 in January 2013, corresponding to years 5 and 6, the random-
point method attenuated the variation observed using mid-point estimation (Figure 3a). The 
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median length of the seroconversion interval was 3.4 months (IQR: 3.0-7.1) for cohort-1 
participants whose last-negative test date occurred before January 2013, and 10.1 months (IQR: 
5.8-18.3) between January 2013 and December 2014, and 3.9 months (IQR: 2.5-5.5) after 
January 2015. In cohort-2 the median was 14.9 months (IQR: 4.7-26.9) between January 2013 
and December 2014, and 5.6 months (IQR: 3.2-7.7) after January 2015. In cohort-2 without MI, 
incidence based on mid-point increased between the first and second intervals peaked at year two 
then decreased steeply at the end of the observation period, while that based on random-point 
dropped from its peak at the first interval and decreased further in the last interval (Figure 3b).  
 
In cohort-1, incidences based on MI using random-point estimation for attrition were higher than 
without MI (using either method), particularly starting from year five. In cohort-2, the 
overlapping 95% CIs for incidences are consistent with no differences between MI and without 
MI approaches.  
 
Based on random-point without MI for attrition, there was a sharp fall in incidence from 6.1/100 
person-years within the first six months to 2.5/100 in the following six months, and then 2.0/100 
at year three in cohort-1 (age-adjusted trend p-value<0.001). After the fourth year, incidence 
increased to 3.8/100 person-years at the end of the observation period but there was weak 
evidence to suggest a changing trend (age-adjusted p-value=0.15). In cohort-2, incidence 
declined from 3.8/100 person-years in the first 6 months to 1.8/100 in year 3 (age-adjusted p-
value=0.04). 
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Discussion 
 
Our findings suggest that the variations in incidence patterns observed with assigning mid-points 
within seroconversion intervals were attenuated if random-points were assigned instead. With 
long seroconversion intervals spanning the observation period, incidences based on mid-point 
were lower at the beginning and at the end of the observation than in the middle where incidence 
peaked (cohort-2). Where long seroconversion intervals were concentrated in the middle of 
observation periods with short seroconversion intervals, there were larger fluctuations in 
incidences over time during that middle period using the mid-point than the random-point 
approach (cohort-1). MI for unobserved HIV sero-status and time-to-seroconversion for women 
defined with attrition showed noticeably higher incidences than without MI following an 
escalated attrition of participants (year 5 in cohort-1 and year 1 in cohort-2).  
 
An incidence peak in the middle of the observation period and lower incidence at the beginning 
and at the end using the mid-point approach is consistent with results from a recent simulation 
study where incidence was underestimated at the beginning and at the end of the observation and 
overestimated in the middle
2
. This mid-point behaviour is a result of clustering of the 
seroconversion timing in the middle of the observation period. The authors observed this pattern 
with a large extent of missed scheduled test dates irrespective of the true incidence trend, cohort 
type and number of scheduled test dates. However, they described incidence patterns where 
irregular HIV testing spans the entire observation period, similar to what we observe in cohort-2. 
Conversely, in their study the random-point assignment of seroconversion date which was less 
restrictive than the mid-point showed less biased incidence trends.   
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Cohort-1 had much longer seroconversion intervals in the period spanning year 5 and 6 than 
during the first four years and years 7 and 8. This resulted in similar incidences for the random-
point and mid-point approaches in the period with shorter seroconversion intervals and 
noticeable differences in the period with longer seroconversion intervals. In 2013 and 2014, 
peer-educators who were instrumental in study recruitment involving high-risk populations were 
not paid allowances. This, together with not providing transport compensation for participants, 
had a negative effect on visit attendance leading to longer seroconversion intervals and a 
subsequent clustering of seroconversion timing at year 5 but offset at the following year. 
 
Although participants in years 7 and 8 had irregular visit attendance similar to that in years 5 and 
6, they had shorter seroconversion intervals suggesting that the length of the seroconversion 
intervals rather than irregular visit attendance determine the extent of differences between the 
two approaches. If for some reason there is irregular visit attendance in general but the 
seroconversion intervals are shorter, then there would be little differences between the 
approaches.  
 
In both cohorts, the higher MI-based than non-MI incidences following escalated attrition of 
participants suggests attrition of more-risky participants, given previously reported 
characteristics. However, it is likely that the estimated MI-based incidences following marked 
attrition may be overestimated if some participants dropped-out because they perceived 
themselves to be low-risk, for example, exited sex work but reported high-risk behaviours at the 
prior visit. For cohort-1, escalated attrition occurred at a time-point corresponding to the 
estimated mean duration of risk behaviours for FSWs in Africa of 5.5 years, as reported in a 
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review of duration of risk behaviours in key populations
21
. Overall, these MI-based estimates 
suggest that incidences obtained without MI may have been underestimated following escalated 
attrition.   
 
A key limitation in this study is the use of self-reported data in predicting sero-status for women 
with attrition, which data is subject to social desirability and can ultimately affect MI-based 
incidence estimates. Also, some women defined with attrition in our study may be accessing 
services elsewhere including private services, may have exited sex work, or are living less-risky 
lifestyles yet their un-observed predicted sero-status is based on previously reported high-risk 
behaviours. Therefore, combined with the lack of proper data on the reasons for exit and data on 
mortality, the MI-based incidences may have been over-estimated. In addition, missing data in 
some women, which was used to perform MI, could potentially skew conclusions. However, we 
assumed these data were missing completely at random because most of the missingness was due 
to the electronic data capture system failing to capture data at roll-out during cohort-2. 
Nonetheless, it is unlikely that these observations could have substantially changed our 
conclusions.  
 
In conclusion, the random-point approach reduced the improbable fluctuations in incidence and 
incidence patterns observed with mid-point in the presence of long seroconversion intervals. 
Based on random-point without MI, the HIV incidence declines in the three years following 
enrolment of 67% in cohort-1 and 53% in cohort-2 were substantial but incidence remains high. 
The declines in HIV incidence over time are likely due to the ongoing interventions but the high 
incidence rates after years of potential exposure to the intervention suggests a need for further 
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strengthening the intervention efforts in this cohort. In particular, the factors influencing the 
slight rise in incidence after four years among cohort-1 participants are not well understood, but 
these changes coincide with the period with substantial proportions of missed visits. We are 
currently examining some of these factors in more detail. Despite the importance of tracking 
HIV incidence trends in this vulnerable population, there was paucity of recent incidence data 
with which to compare our findings
10,21,22
. In choosing how to assign the seroconversion timing 
and interpreting the resulting incidence patterns, it is important to consider the changes in the 
extent of missed visits and length of seroconversion intervals over time. 
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Figure 2: Distribution for the number of missed visits between consecutive visits attended 
following enrolment by cohort of enrolment. 
 
Figure 3. Compares HIV incidence trends based on three methods, by cohort: 1) Without 
multiple imputation (Ml) for attrition using the mid-point method; (2) Without MI using 
random-point; (3) With MI for attrition using random-point. 95% Confidence intervals 
are shown only for the preferred method of random-point. 
Notes: MI was based on 30 imputed datasets and combined rates using Rubin's rules. The 
imputation model for MI included age, number of partners in the last month, reporting paid sex, 
frequency of condom use in the last month with paid sex, frequency of alcohol consumption, source 
of income, number of children and marital status. Random-point estimation of the seroconversion 
date was based on 200 imputations, more than 3 times imputations required for convergence. 
95% confidence intervals are shown for only random-point estimation of HIV seroconversion with 
and without MI. Missing data in some of the variables in the imputation model were mainly 
because some data was not captured as electronic data capture was being rolled-out in January 
2015. Therefore, we assumed that this data was missing completely at random (MCAR), and 
multiple imputation that involved these variables was not conducted for these women. 
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Figure 1 
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Figure 2 
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Figure 3 
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Table 1: Characteristics at enrolment for HIV-negative women enrolled into the GHWP between 31
st
 March 2008 and 1
st
 May 
2017, and a comparison of women who remained in each cohort with those defined with attrition. 
Characteristic at enrolment  Cohort-1  Cohort-2 
  All Successfully 
followed, n (%) 
Loss to follow-
up, n (%) 
All1 Successfully 
followed, n (%) 
Loss to follow- 
up, n (%) 
Total 647 221 426 2437 1243 1194 
Age in years <24 291  (45.0) 92  (41.6) 199  (46.7) 1059  (44.6) 528  (43.5) 531  (45.6) 
25-34 298  (46.1) 107  (48.4) 191  (44.8) 1008  (42.4) 511  (42.1) 497  (42.7) 
35+ 58    (9.0) 22  (10.0) 36  (8.5) 310    (13.0) 174  (14.3) 136  (11.7) 
 
    
60 
  Highest 
education level  
Less than primary 284  (43.9) 99  (44.8) 185  (43.4) 907  (40.8) 458  (41.8) 449  (39.8) 
Completed Primary 281  (43.4) 96  (43.4) 185  (43.4) 940  (42.2) 443  (40.4) 497  (44.1) 
Completed Secondary Ordinary level 82  (12.7) 26  (11.8) 56  (13.1) 378  (17.0) 196  (17.9) 182  (16.1) 
 
    
212 
  Marital status  Widowed/divorced 417  (64.5) 147  (66.5) 270  (63.4) 1447  (60.7) 723  (59.3) 724  (62.3) 
Currently married 52  (8.0) 19  (8.6) 33   (7.7) 163  (6.8) 86  (7.1) 77  (6.6) 
Never married 178  (27.5) 55  (24.9) 123  (28.9) 772  (32.4) 410  (33.6) 362  (31.1) 
 
    
55 
  Number of 
children  
None 85  (13.1) 16  (7.2) 69  (16.2) 399  (17.0) 211  (17.6) 188  (16.3) 
One 169  (26.1) 63  (28.5) 106  (24.9) 612  (26.1) 296  (24.7) 316  (27.5) 
At least 2 393  (60.7) 142  (64.3) 251  (58.9) 1337  (56.9) 690  (57.6) 647  (56.2) 
 
    
89 
  Source of 
income 
Sex work alone 379  (58.6) 133  (60.2) 246  (57.7) 1371  (57.9) 732  (60.6) 639  (55.1) 
Sex work and other job 242  (37.4) 80  (36.2) 162  (38.0) 876  (37.0) 430  (35.6) 446  (38.5) 
No sex work 26  (4.0) 8  (3.6) 18  (4.2) 119  (5.0) 45  (3.7) 74  (6.4) 
 
    
71 
  Where paying 
clients are 
recruited from 
Bar, club or restaurant 334  (52.7) 117  (54.2) 217  (51.9) 1062  (48.1) 564  (49.0) 498  (47.1) 
Street 82  (12.9) 32  (14.8) 50  (12.0) 693  (31.4) 381  (33.1) 312  (29.5) 
Several avenues 218  (34.4) 67  (31.0) 151  (36.1) 452  (20.5) 205  (17.8) 247  (23.4) 
                                                          
1
 Most missing data were due to programming errors in the electronic data capture system as the system was rolled-out starting in January 2015. 
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 missing 13 5 8 230 
  Pregnancy 
status 
Not pregnant 585  (90.4) 197  (89.1) 388  (91.1) 2273  (96.8) 1161  (98.1) 1112  (95.5) 
Pregnant 62  (9.6) 24  (10.9) 38  (8.9) 76  (3.2) 23  (1.9) 53  (4.5) 
 
    
88 
  Current 
contraceptive 
use 
none or other 364  (56.3) 124  (56.1) 240  (56.3) 1449  (65.7) 724  (66.1) 725  (65.4) 
oral cc 63  (9.7) 20  (9.0) 43  (10.1) 142  (6.4) 79  (7.2) 63  (5.7) 
inject 158  (24.4) 53  (24.0) 105  (24.6) 538  (24.4) 270  (24.6) 268  (24.2) 
 Pregnant 62  (9.6) 24  (10.9) 38  (8.9) 76  (3.4) 23  (2.1) 53  (4.8) 
 
    
232 
  Frequency of 
paid sex in the 
last 12 months at 
enrolment 
Less than once a week/None 92  (14.2) 29  (13.1) 63  (14.8) 308  (12.8) 127  (10.4) 181  (15.4) 
At least once a week 256  (39.6) 89  (40.3) 167  (39.2) 689  (28.7) 353  (28.9) 336  (28.5) 
Daily 299  (46.2) 103  (46.6) 196  (46.0) 1404  (58.5) 743  (60.8) 661  (56.1) 
    
36 
  Number of 
sexual partners 
in the last month 
<5 208  (32.1) 67  (30.3) 141  (33.1) 545  (24.6) 241  (22.0) 304  (27.0) 
5-19 200  (30.9) 74  (33.5) 126  (29.6) 471  (21.2) 246  (22.5) 225  (20.0) 
At least 20 239  (36.9) 80  (36.2) 159  (37.3) 1203  (54.2) 606  (55.4) 597  (53.0) 
 
    
218 
  Number of 
paying partners 
in the last month 
<5 227  (35.1) 80  (36.2) 147  (34.5) 562  (25.4) 249  (22.8) 313  (27.9) 
5-19 193  (29.8) 64  (29.0) 129  (30.3) 457  (20.7) 237  (21.7) 220  (19.6) 
At least 20 or cannot remember 227  (35.1) 77  (34.8) 150  (35.2) 1193  (53.9) 604  (55.4) 589  (52.5) 
 
    
225 
  Condom use 
frequency with 
paid sex in the 
last month 
Inconsistent 214  (33.1) 75  (33.9) 139  (32.6) 969  (43.4) 496  (45.0) 473  (41.9) 
Consistent (always) 359  (55.5) 127  (57.5) 232  (54.5) 1007  (45.1) 487  (44.2) 520  (46.1) 
No paid sex 74  (11.4) 19  (8.6) 55  (12.9) 255  (11.4) 120  (10.9) 135  (12.0) 
    
206 
  Alcohol 
consumption 
frequency  
Non-drinker 160  (24.7) 51  (23.1) 109  (25.6) 531  (23.0) 280  (23.9) 251  (22.0) 
Non-daily drinker 332  (51.3) 115  (52.0) 217  (50.9) 886  (38.4) 427  (36.5) 459  (40.3) 
Daily drinker 155  (24.0) 55  (24.9) 100  (23.5) 892  (38.6) 463  (39.6) 429  (37.7) 
 
    
128 
  Binge drinking in 
last 3 months 
Non drinker 160  (24.7) 51  (23.1) 109  (25.6) 530  (22.6) 280  (23.6) 250  (21.6) 
No binging 325  (50.2) 114  (51.6) 211  (49.5) 396  (16.9) 179  (15.1) 217  (18.8) 
Binged 162  (25.0) 56  (25.3) 106  (24.9) 1414  (60.4) 725  (61.2) 689  (59.6) 
 
    
97 
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Illicit drug use in 
last 3 months 
No 529  (81.8) 170  (76.9) 359  (84.3) 1548  (69.6) 782  (71.3) 766  (68.0) 
Yes 118  (18.2) 51  (23.1) 67  (15.7) 676  (30.4) 315  (28.7) 361  (32.0) 
 
    
213 
  When the 
participant last 
tested prior to 
enrolment 
>1 year ago or never 408  (63.1) 138  (62.4) 270  (63.4) 582  (24.8) 268  (22.3) 314  (27.4) 
7-12 months ago 110  (17.0) 36  (16.3) 74  (17.4) 294  (12.5) 151  (12.6) 143  (12.5) 
<6 months ago 129  (19.9) 47  (21.3) 82  (19.2) 1470  (62.7) 783  (65.1) 687  (60.1) 
    
91 
  Ever 
experienced 
gender based 
violence by type 
of partner 
Never 
   
1308  (59.3) 606  (55.7) 702  (62.8) 
Marital or non-paying partners 
   
458  (20.8) 240  (22.1) 218  (19.5) 
Paying clients 
   
397  (18.0) 218  (20.0) 179  (16.0) 
Several of above/DK 
   
43  (1.9) 24  (2.2) 19  (1.7) 
missing 
   
231 
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Table 2: Study participation and follow-up status at each follow-up time interval by enrolment cohort  
 Cohort-1 (closed cohort) Cohort-2 (open cohort) 
 
Retention Status at the end follow-up  Retention Status at the end follow-up 
Time interval  
 
 
 
 
(years) 
Women 
expecte
d at the 
start of 
each 
interval 
Cohort 
retention at 
end of 
interval†,  
n (%) 
Women 
without 
a single 
follow-
up visit 
HIV-
negativ
e 
followe
d-up to 
end of 
interval 
Attriti
on by 
end 
of 
interv
al⁑ 
Administ
ratively 
censored 
HIV 
incide
nt 
cases 
(Sero-
conve
rters) 
Women 
expected 
at the 
start of 
each 
interval* 
Cohort 
retention at 
end of 
interval†,  
n (%) 
Women 
without a 
single 
follow-up 
visit 
HIV-
negativ
e 
followe
d-up to 
end of 
interval 
Attritio
n by 
end of 
interval
⁑ 
Administr
atively 
censored 
HIV 
incident 
cases 
(Sero-
convert
ers) 
Enrolled 647 647  (100.0) 42 - - - - 2,437 2437  (100.0) 836 - - - - 
0 - 0.5 647 582  (90.0) - 570 23 - 12 2,338 1692 (72.4) - 1,332 134 120 15 
0.5 - 1 647 563  (87.0) - 540 19 - 11 2,065 1197  (58.0) - 997 150 171 14 
1 - 2 647  524  (81.0)  485 39 - 16 1,731 650    (45.4)  488 211 272 26 
2 - 3 647 491  (75.9) - 444 32 - 8 1,026 450    (43.9) - 254 77 142 15 
3 - 4 647 429  (66.3) - 375 63 - 7 676 300     (44.4) - 41 11 236 7 
4 - 5 ‡ 647 375  (58.0) - 313 54 - 8       
 
5 - 6 647 331  (51.2) - 264 44 - 4        
6 - 7 647 267  (41.3) - 189 64 - 12 
       
7 - 8 647 203  (31.4) - 116 46 18 9 
       
End of follow-up 
 
- - 
 
110 6 
       ‡For cohort-2, the last interval of follow-up ends at time interval of 3-4 years, †cohort retention defined as the number of women followed-up to each time interval including those who had 
seroconverted among those who should have been followed by that time point, ⁑A participant is classified with attrition (drop-out) if their last attended visit was 12 months or more prior to 29th 
August, 2017. Participants were administratively censored if their last attended visit was within the last 12 months from the administrative date of 29th August 2017. *Participants expected at the start 
of each interval for cohort-2 vary because of continuous enrolment, meaning that to be included in an interval the participant should have been enrolled for that duration.   
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Table 3: HIV incidence rates and associated 95% confidence intervals (CI) for each of the three analytic methods, by time 
since enrolment for each cohort. 
  
Cohort-1           Cohort-2     
    
Years since 
enrolment 
Mid-point without  
multiple imputation 
 Random-point 
without multiple 
imputation 
 Random-point 
with multiple 
imputation 
 Mid-point without  
multiple 
imputation 
 Random-point 
without multiple 
imputation 
 Random-point 
with multiple 
imputation 
  
[per 100 pyr (95% 
CI)] 
 
[per 100 pyr 
(95% CI)] 
 
[per 100 pyr 
(95% CI)] 
 
[per 100 pyr 
(95% CI)] 
 
[per 100 pyr 
(95% CI)] 
 
[per 100 pyr 
(95% CI)] 
Combined 3.1 (2.5-3.8) 
 
3.1 (2.5-3.8) 
 
4.8 (4.2-5.5) 
 
3.0 (2.4-3.8) 
 
3.0 (2.4-3.8) 
 
3.2 (2.7-3.8) 
0.5 5.8 (3.6 - 9.3) 
 
6.1 (3.8 - 9.7) 
 
6.1 (3.9 - 9.6) 
 
3.1 (2.0 - 4.6) 
 
3.8 (2.6 - 5.5) 
 
3.5 (2.5 - 5.0) 
1 2.9 (1.5 - 5.8) 
 
2.5 (1.2 - 5.4) 
 
3.8 (2.2 - 6.9) 
 
3.5 (2.3 - 5.5) 
 
2.8 (1.7 - 4.6) 
 
4.0 (2.8 - 5.7) 
2 3.1 (1.9 - 5.1) 
 
3.2 (2.0 - 5.2) 
 
3.6 (2.4 - 5.6) 
 
3.7 (2.5 - 5.4) 
 
3.2 (2.1 - 4.8) 
 
3.0 (2.2 - 4.0) 
3 1.7 (0.9 - 3.4) 
 
2.0 (1.1 - 3.9) 
 
2.6 (1.4 - 4.1) 
 
1.5 (0.8 - 3.1) 
 
1.8 (1.0 - 3.5) 
 
2.7 (1.9 - 3.8) 
4 1.9 (1 - 3.9) 
 
1.9 (0.9 - 3.9) 
 
3.0 (1.9 - 4.9) 
     
  
5 4.7 (2.9 - 7.7) 
 
3.3 (1.8 - 5.9) 
 
6.3 (4.3 - 8.6) 
     
  
6 1.4 (0.5 - 3.8) 
 
2.3 (1.1 - 5.1) 
 
4.7 (2.9 - 6.9) 
     
  
7 3.7 (1.8 - 7.3) 
 
3.6 (1.8 - 7.3) 
 
6.8 (4.7 - 9.7) 
     
  
8 3.8 (1.9 - 7.5)   3.8 (1.9 - 7.5)   5.9 (4.4 - 8.5)             
Pyr – person-years of follow-up, 95% CI – 95% confidence intervals 
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